Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk has halved the US price for Ozempic for people who cannot access it on health insurance and offered it for home delivery as the Trump administration pushes for lower drug prices and more ...

U.S. stock futures edged lower Monday, while Treasuries gained, as traders focused on progress toward a potential peace deal for Ukraine and awaited signals from the Federal Reserve on interest rates.

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to ...

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...

Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.